A 72-year-old woman on warfarin (INR 8.2) for atrial fibrillation presents with sudden-onset left-sided weakness and expressive speech difficulty. CT head shows a right frontal lobar hemorrhage (35 mL) with 8 mm midline shift. Platelet count is 180,000/μL, PT/INR 8.2, aPTT 45 seconds. What is the most appropriate initial coagulation reversal strategy?

Explanation

## Clinical Diagnosis This patient has **warfarin-associated intracerebral hemorrhage (ICH)** with significant coagulopathy (INR 8.2). The presentation includes: - Acute focal neurological deficit (left hemiparesis, expressive aphasia) - Significant ICH volume (35 mL) with mass effect (8 mm midline shift) - Severe supratherapeutic INR on warfarin ## Coagulation Reversal in Warfarin-Associated ICH **Key Point:** Rapid reversal of warfarin-induced coagulopathy is critical in ICH to prevent hematoma expansion. Current evidence strongly favors **prothrombin complex concentrate (PCC)** over fresh frozen plasma (FFP). **High-Yield:** Evidence-based hierarchy for warfarin reversal in ICH: 1. **PCC (25 units/kg IV)** — Preferred first-line agent - Rapid onset (15–30 minutes) - Concentrated vitamin K-dependent factors (II, VII, IX, X) - Smaller volume → less fluid overload - Superior to FFP in reducing hematoma expansion (INCH trial principles) 2. **Vitamin K 10 mg IV** — MUST be given concurrently (takes 12–24 hours to work; PCC provides immediate reversal) 3. **FFP** — Only if PCC unavailable; requires large volumes (15 mL/kg = ~1000 mL), risks fluid overload and pulmonary edema **Mnemonic:** **PCC First, K Always** = Use PCC immediately + vitamin K IV together in warfarin-associated ICH. ## Mechanism of Action ```mermaid flowchart TD A[Warfarin-associated ICH<br/>INR >4]:::outcome --> B{Coagulation reversal needed}:::decision B -->|Immediate reversal<br/>15-30 min| C[PCC 25 units/kg IV]:::action B -->|Sustained reversal<br/>12-24 hrs| D[Vitamin K 10 mg IV]:::action C --> E[Restores factors II, VII, IX, X]:::outcome D --> F[Promotes synthesis of<br/>vitamin K-dependent factors]:::outcome E --> G[INR reduction<br/>Hematoma expansion prevention]:::outcome F --> G H[FFP 15 mL/kg<br/>if PCC unavailable]:::action -.->|Slower, larger volume| G ``` **Clinical Pearl:** PCC is superior to FFP because it achieves INR <4 in ~15–30 minutes with minimal volume, whereas FFP requires 1000+ mL and takes longer. In ICH, time and volume matter. ## Why This Answer is Correct Option 1 (PCC + vitamin K immediately) is correct because: - **PCC provides rapid reversal** (15–30 min) of warfarin effect - **Vitamin K ensures sustained reversal** (takes 12–24 hours but essential for long-term INR control) - **Both given together** = immediate + sustained reversal - **No delay** waiting for 24-hour INR check (as in option 0) - **Guideline-concordant**: AHA/ASA 2019 and American College of Chest Physicians (ACCP) recommend PCC as first-line ## Why Other Options Are Wrong | Option | Why Incorrect | |--------|---------------| | **Option 0: FFP + vitamin K, then PCC later** | FFP is inferior to PCC: slower onset (60–90 min), requires large volume (1000+ mL), risks fluid overload/pulmonary edema. Delaying PCC for 24 hours allows continued hematoma expansion. PCC should be first-line, not second-line. | | **Option 2: Vitamin K alone** | Vitamin K takes 12–24 hours to work. In acute ICH, this delay allows hematoma expansion and neurological deterioration. Immediate reversal with PCC is mandatory. | | **Option 3: FFP + idarucizumab** | Idarucizumab is a monoclonal antibody that reverses **dabigatran** (DOAC), not warfarin. It is contraindicated and ineffective in warfarin-associated ICH. FFP is also suboptimal (see option 0). | [cite:Harrison 21e Ch 297; AHA/ASA Stroke Guidelines 2019]